Abstracts Archive - Page 1596 of 2607 - ACR Meeting Abstracts

Abstract Number: 3 • 2017 Pediatric Rheumatology Symposium
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Rayfel Schneider⁴, Isabelle Koné-Paut⁵, Kenneth N. Schikler⁶, Katherine Marzan⁴, Nico Wulffraat², Shai Padeh⁷, Vyacheslav Chasnyk⁷, Carine Wouters⁷, Jasmin B. Kuemmerle-Deschner⁷, Tilmann Kallinich⁷, Bernard Lauwerys⁸, Elie Haddad⁴, Evgeny L Nasonov⁷, Maria Trachana⁷, Olga Vougiouka⁷, Karolynn Leon⁹, Antonio Speziale¹⁰, Karine Lheritier¹⁰, Eleni Vritzali¹¹, Alberto Martini⁷ and Daniel Lovell⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴PRCSG, Cincinnati, OH, ⁵Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁶PRCSG, Cincinatti, OH, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic arthritis…
Abstract Number: 91 • 2017 Pediatric Rheumatology Symposium
Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height
Merav Heshin-Bekenstein¹, Aimee O. Hersh², Emily von Scheven³ and Erica Lawson¹, ¹Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ²Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ³Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA
Background/Purpose: Patients with childhood-onset SLE (cSLE) have a higher incidence of renal disease and may receive more intensive immunosuppression as compared to individuals with adult-onset…
Abstract Number: 44 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Isabelle Koné-Paut⁴, Katherine Marzan⁵, Nico Wulffraat², Rayfel Schneider⁵, Shai Padeh⁶, Vyacheslav Chasnyk⁶, Carine Wouters⁶, Jasmin B. Kuemmerle-Deschner⁶, Tilmann Kallinich⁶, Bernard Lauwerys⁷, Elie Haddad⁵, Evgeny L Nasonov⁶, Maria Trachana⁶, Olga Vougiouka⁶, Karolynn Leon⁸, Eleni Vritzali⁹, Karine Lheritier¹⁰, Alberto Martini⁶ and Daniel Lovell⁵, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁵PRCSG, Cincinnati, OH, ⁶PRINTO-Istituto Gaslini, Genova, Italy, ⁷Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The management of SJIA with biological therapies is aimed to achieve and maintain clinical remission (CR), and accordingly taper corticosteroids (CS). Canakinumab (CAN) demonstrated…
Abstract Number: 54 • 2017 Pediatric Rheumatology Symposium
Treatment and 1-year outcomes of an inception cohort of Australian children with JIA
Georgina Tiller¹, Jo Buckle², Jane Munro³, Angela Cox², Peter Gowdie², Roger Allen⁴ and Jonathan Akikusa^5,6, ¹Rheumatology, Royal Childrens Hospital, Parkville, Australia, ²Rheumatology, Royal Children's Hospital, Melbourne, Australia, ³Rheumatology, Royal Children's Hospital, Parkville, Australia, ⁴Paediatric Consulting Centre, Royal Childrens Hospital, Melbourne, VIC, Australia, ⁵Arthritis and Rheumatology Research, Murdoch Childrens Research Institute, Parkville, Australia, ⁶3 West Clinical Offices, Royal, Royal Children's Hospital, Melbourne, Australia
Background/Purpose: Recent studies have provided insight into the short and intermediate term outcomes of cohorts of children with JIA managed with contemporary treatments in North…
Abstract Number: 7 • 2017 Pediatric Rheumatology Symposium
Activation of Immature, Transitional B cells by Integrated BCR, TLR and TACI signals promotes systemic autoimmunity in high BAFF settings
Holly Jacobs, Samuel Du, Tanvi Arkatkar and Shaun Jackson, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: B cell activating factor of the TNF family (BAFF, also known as BLyS) promotes B cell survival and activation by binding distinct B cell…
Abstract Number: 77 • 2017 Pediatric Rheumatology Symposium
Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard R. Lauwerys⁴, Antonio Speziale⁵, Xiaoling Wei⁶ and Ronald Laxer⁷, ¹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Unité romande d’immuno-rhumatologie pédiatrique, CHUV, University of Lausanne, Genova, Italy, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Service de rhumatologie, Pôle de pathologies rhumatismales inflammatoires et systémiques, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis, Shanghai, China, ⁷Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Canakinumab (CAN) has been shown not to impair antibody production following vaccination in children in an open-label phase 3 study (NCT01302860).1 Here we present the…
Abstract Number: 59 • 2017 Pediatric Rheumatology Symposium
Six Minute Walk Test in Children with Juvenile Idiopathic Arthritis
Dax G. Rumsey^1,2, Cara Kaup², Michelle Roy², Lyne Bourassa³, Elham Khodayari Moez⁴, Olaf Verschuren⁵ and Lesley Pritchard-Wiart^2,6, ¹Paediatrics, University of Alberta, Edmonton, AB, Canada, ²Glenrose Rehabilitation Hospital Edmonton, Edmonton, AB, Canada, ³Physical Therapy, University of Alberta, Edmonton, Netherlands, ⁴School of Public Health, University of Alberta, Edmonton, AB, Canada, ⁵Brain Center Rudolf Magnus and Center of Excellence for Rehabilitation Medicine, University Medical Centre Utrecht, Utrecht, Netherlands, ⁶Physical Therapy, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The 6-minute walk test (6MWT) is a widely used measure of functional exercise capacity. It has not, however, been routinely used in pediatric rheumatology…
Abstract Number: 126 • 2017 Pediatric Rheumatology Symposium
Challenges in Transitioning Adolescents with Rheumatologic Diseases to Adult Care – The Brazilian Experience
Ana Paula Sakamoto¹, Catherine Anelli¹, Ana Luiza Amorim¹, Fabiane Osaku², Maria Teresa Terreri¹, Claudio A. Len³ and Andreas Reiff⁴, ¹Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ²Pediatric Rheumatology, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ³Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo,, Brazil, ⁴Division of Rheumatology MS 60, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, USA, Los Angeles, CA
Background/Purpose: Due to the high survival rates in chronic pediatric rheumatologic diseases a well-structured and effective transition process becomes crucial to guarantee continuity of care…
Abstract Number: 106 • 2017 Pediatric Rheumatology Symposium
Atypical manifestations and main misdiagnoses of Takayasu’s arteritis in childhood: a multicenter study of 71 patients
Gleice Clemente¹, Ana Paula Sakamoto², Silvana B. Sacchetti Sr.³, Virgínia Ferriani⁴, Flavio Sztajnbok⁵, Sheila Oliveira⁶, Blanca Bica⁷, Andre Cavalcanti⁸, Teresa Robazzi⁹, Marcia Bandeira¹⁰ and Maria Teresa Terreri², ¹Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Univesidade Federal de São Paulo), São Paulo, Brazil, ²Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ³Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁴Department of Pediatrics School of Medicine of Ribeirão Preto, University of São Paulo (USP-RP), Ribeirão Preto, Brazil, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, ⁶Pediatric Rheumatology, Universidade F Rio De Janeiro, Rio De Janeiro, Brazil, ⁷Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil, ⁸Novartis, Sao Paulo, Brazil, ⁹Pediatrics, Universidade Federal da Bahia, Salvador, Brazil, ¹⁰Pediatric Rheumatology Unit, Hospital Pequeno Príncipe, Curitiba, Brazil
Background/Purpose: Takayasu’s arteritis is a chronic inflammatory disease that affects the wall of large and medium-sized blood vessels. At the beginning of the disease, non-specific…
Abstract Number: 20 • 2017 Pediatric Rheumatology Symposium
Enthesitis-Related Arthritis: Non-Peripheral Pattern is Associated with an Expansion of Peripheral Th17 Populations
Maria M. Katsicas¹, Carolina Carrara², Andrea Bernasconi³, Jorge Rossi⁴ and Ricardo Russo⁵, ¹Service of Immunology & Rheumatology., Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, ²Immunology& Rheumatology, Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, ³Immunology &Rheumatology, Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, ⁴Immunology & Rheumatology, Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, ⁵Immnology & Rheumatology, Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina
Background/Purpose: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis. Different proinflammatory cytokines linked to the Th1 and Th17 T- cell subsets have been…
Abstract Number: 43 • 2017 Pediatric Rheumatology Symposium
Tocilizumab Use in Pediatrics With Systemic Juvenile Idiopathic Arthritis: Single Center Data
Swati Jain¹, M. Brooke Bernhardt¹, Andrea A. Ramirez², Anna Carmela Sagcal-Gironella³ and Marietta de Guzman⁴, ¹Pharmacy, Texas Children's Hospital, Houston, TX, ²Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Tocilizumab is a humanized monoclonal antibody against interleukin-6 receptors and is indicated for the treatment of systemic juvenile idiopathic arthritis (sJIA) in patients 2…
Abstract Number: 112 • 2017 Pediatric Rheumatology Symposium
Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder
Sabrina Gmuca¹, Amy T. Waldman², Pamela F. Weiss³ and Jeffrey S. Gerber², ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: First-line use of rituximab for neuromyelitis optica spectrum disorder (NMOSD) is common but the benefits of early immunosuppression remain unclear. We aimed to determine…
Abstract Number: 132 • 2017 Pediatric Rheumatology Symposium
Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study
Amanda R. Schlefman¹, Megan M. Simonds², Kathleen E. Sullivan³, Carlos D. Rosé¹ and AnneMarie C. Brescia¹, ¹Pediatric Rheumatology, Nemours/Thomas Jefferson University, Wilmington, DE, ²Nemours Biomedical Research, Wilmington, DE, ³Pediatrics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: A chondrocyte-like phenotype has previously been described in pediatric fibroblast-like synoviocytes (FLS), which may contribute to bony overgrowth in juvenile idiopathic arthritis (JIA). The…
Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium
Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Kelly Wise¹, Dustin Lewis², Bethanne Thomas², Karla Jones³, Stephanie Lemle², Darby MacDonald², Fatima Barbar-Smiley², Vidya Sivaraman² and Cagri Yildirim-Toruner³, ¹Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes. Biologics,…
Abstract Number: 119 • 2017 Pediatric Rheumatology Symposium
Establishment of registry for pediatric rheumatic diseases in Japan: Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey
Tomoyuki Imagawa¹, Ken-ichi Yamaguchi², Yuzaburo Inoue³, Hidehiko Narasaki⁴, Yasuhito Nerome⁵ and Yasuhiko Itoh⁴, ¹Department of Infectious diseases and Immunology, Kanagawa Children’s Medical Center, Yokohama, Japan, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Department of Pediatrics, Eastern Chiba Medical Center, Togane, Japan, ⁴Department of Pediatrics, Nippon Medical School, Tokyo, Japan, ⁵Department of Community-Based Medicine Education Center for Doctors in Remote Islands and Rural Areas, Kagoshima University, Kagoshima, Japan
Background/Purpose: To identify the number and characteristics of Japanese pediatric diseases, Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey was established by Pediatric Rheumatology Association…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].